Provider review
Try Ageless Review: It Sells Tirzepatide Drops No Trial Has Ever Tested
Try Ageless sells three weight-loss products and describes two of them accurately: the semaglutide injection cites STEP-1, the tirzepatide injection cites SURMOUNT-1, both with the right trial length attached to the right molecule. The third is a daily sublingual liquid it calls "tirzepatide without the needle", and no registered trial has tested tirzepatide by that route.
Try Ageless is careful in two places and reckless in one. Its injectable claims are the kind this site rarely gets to praise — the trial is named, the duration is stated, the molecule is right, and the registry agrees on all three. Its price disclosure is better than most: the standing rate is printed beside the prepay ladder instead of behind it. Then it sells a daily sublingual drop as "tirzepatide without the needle" at the lowest price in its catalog, and that product has no trial behind it at all — not a weak trial, not a small trial, none. Every one of the 91 completed tirzepatide studies used a weekly injection, because tirzepatide is a 39-amino-acid peptide and route is the whole question for a molecule that size. A buyer choosing drops to save $150 a month is not buying a cheaper version of the thing SURMOUNT-1 tested; they are buying something nobody has tested. Add an operator that FDA wrote to last September about its other website, a batch-testing claim with no document behind it, and a homepage still quoting prices whose pages are gone, and the sensible reading is: the injections are what the evidence covers, and the drops are not.
Worth trusting if
- You want the price before the questions, because every product page prints one and the intake asks nothing until after you have seen it.
- You are buying an injection, where the 14.9% and the SURMOUNT-1 figures are named, dated and matched to the right molecule.
- You would rather see a real month-to-month rate than a prepay ladder, because both the total and the per-month equivalent are published.
Be skeptical if
- You are buying the sublingual drops to save money, because no completed trial has tested tirzepatide by any route other than injection.
- You want a firm number before handing over details, because the site says the final amount arrives only after a clinician reviews you.
- You will not create a password-protected account to finish an intake, because that is where the six questions end.
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens tryageless.com. A link is not a recommendation to take anything.
Provenance
What Try Ageless actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Semaglutide + B12 (weekly injection) — $175 every month paying month to month, re-read 2026-08-25. The ladder below it: $435 every 3 months, $720 every 6, and $1,188 for a year, which is the "$99/mo" the page leads with. This review previously said $279 month-to-month against a $2,388 yearly plan; both figures were read on 2026-08-11 and neither is on the page now. The product page disagrees with the ladder page on the same day: /product/semaglutide-b12-injection/ shows $99 struck from $229 "for a month supply", where the treatments page shows $175 — and the product page adds that the "exact pricing depends on your prescribed dose" and the final amount only appears after clinical review.
- Tirzepatide + B12 (weekly injection) — $235 every month paying month to month, re-read 2026-08-25, with $597 every 3 months, $1,050 every 6 and $1,800 for a year — the last of which is the "$150/mo" headline. Every figure this review carried on 2026-08-11 has moved: it said $349 month-to-month against a $2,988 yearly plan with $987 and $1,794 in between, and none of those four appear on the page today. /product/tirzepatide-b12-injection/ no longer resolves to a product page at all — it redirects to the treatments page, so the ladder above is the only tirzepatide injection price the site publishes.
- Tirzepatide Drops (daily sublingual) — $199 every month, struck from $299, with $549 every 3 months, $1,074 every 6 and $1,908 for a year — the "$159/mo" on the card. These three figures were unchanged between 2026-08-11 and 2026-08-25, the only prices on this page that held. What has changed is the gap this review used to quote: the drops were called the cheapest tirzepatide here "by $150 a month", and against today's $235 injection the difference is $36. The product page contradicts the ladder — /product/tirzepatide-oral-drop/ shows $249 struck from $299 for a one-month supply on the same day the treatments page shows $199.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 3 products reviewed here. The evidence belongs to the molecule, not to Try Ageless.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Try Ageless’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Semaglutide + B12 (weekly injection)Semaglutide · Compounded (503A)Claim matches the trials
“Semaglutide + B12 — INJECTION · SEMAGLUTIDE (GLP-1). The original GLP-1 weight loss injection. Once-weekly subcutaneous injection with B12 for energy support. Average 14.9% body weight loss in Phase 3 trials over 68 weeks.”
Read on the Try Ageless site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Verified in the registry on 2026-08-11: Completed, phase 3, 1,961 participants over 68 weeks. It tested Novo Nordisk's approved semaglutide with lifestyle intervention in both arms — not a compounded preparation from any seller.
The number, the trial length and the molecule all line up, and Try Ageless does something most of this category does not: it states the duration ("over 68 weeks") rather than presenting 14.9% as an open-ended promise. STEP-1 reported mean weight loss of about 14.9% at 68 weeks, and the claim is attributed to "Phase 3 trials" rather than to Try Ageless's own product. Two things the sentence leaves out. STEP-1 gave lifestyle intervention to every arm, so the figure is not what the drug does alone; and the trial tested the FDA-approved product, whereas what Try Ageless dispenses is a compounded preparation that has never been through a registered trial of any kind.1
Tirzepatide + B12 (weekly injection)Tirzepatide · Compounded (503A)Claim matches the trials
“Tirzepatide + B12 — INJECTION · TIRZEPATIDE (GLP-1/GIP). The next-generation dual GLP-1 + GIP agonist. Activates two separate metabolic receptor pathways simultaneously for greater average weight loss than semaglutide. […] Avg body weight lost with tirzepatide in 72-week SURMOUNT-1 trial.”
Read on the Try Ageless site, August 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Verified in the registry on 2026-08-11: Completed, phase 3, 2,539 participants over 72 weeks, testing the approved injectable at a titrated therapeutic dose.
The mechanism sentence is correct — tirzepatide is a dual GIP/GLP-1 receptor agonist — and the trial is named, dated and correctly matched to the molecule. The comparative deserves one caution. "Greater average weight loss than semaglutide" is stated on a page that cites SURMOUNT-1 and STEP-1, which are two separate trials with different populations and protocols; a difference read across two trials is not the same evidence as a head-to-head. Try Ageless does not cite a head-to-head, and this review does not supply one on its behalf. As with every compounded product here, the trials tested the branded injectable, not what is dispensed.2
Tirzepatide Drops (daily sublingual)Tirzepatide · Compounded (503A)No trial supports this claim
“Tirzepatide Drops — Daily sublingual liquid drops — tirzepatide without the needle. Applied under the tongue each day. Travel-friendly, no refrigeration required. The lowest-cost tirzepatide format. […] Tirzepatide active ingredient · Lowest price of any tirzepatide format · USP-grade pharmaceutical purity.”
Read on the Try Ageless site, August 2026
No trial for this use
What the trials show for Tirzepatide
No registered trial has tested tirzepatide sublingually. Checked on 2026-08-11 against the ClinicalTrials.gov v2 API: "sublingual tirzepatide" returns 0 completed studies, "tirzepatide sublingual" returns 0, and "oral tirzepatide drops" returns 0. A bare "tirzepatide" search in the same pass returns 91 completed studies, so these zeros are a finding rather than a broken search. Every trial in the tirzepatide program, SURMOUNT-1 included, administered a once-weekly SUBCUTANEOUS INJECTION. Tirzepatide is a 39-amino-acid peptide, and peptides of that size are the standard example of poor oral and mucosal bioavailability; the one oral GLP-1 that reached approval, semaglutide tablets, required a dedicated absorption enhancer and its own phase 3 program to establish that anything arrived. Nothing equivalent exists for tirzepatide by any non-injected route.
"Tirzepatide without the needle" moves the entire evidence base across a route change that nobody has tested. The 72-week SURMOUNT-1 result belongs to a weekly subcutaneous injection; it says nothing about what a daily drop under the tongue delivers, because absorption is exactly what changes. "USP-grade pharmaceutical purity" and "Tirzepatide active ingredient" are claims about the raw material, not about whether the dose reaches the bloodstream — a pure peptide that is not absorbed is a pure peptide that does nothing. The price framing compounds it: at $199 a month this is presented as the budget way to take tirzepatide, which invites a reader to swap a form with 91 completed trials behind it for one with none on grounds of cost.2
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named. Try Ageless states that its products are "compounded by state-licensed 503A pharmacies" and that "all medications sourced and dispensed from U.S. compounding pharmacies. No overseas product." That is a category and an origin, not an identity: no pharmacy name, no state, no license number and no address appear anywhere on the weight-loss pages. Stating 503A outright still puts it ahead of most of the companies we track, which state no category at all. Its own corporate identity IS published, and it matters — the footer reads "Operated by Lovely Meds, Inc · 131 Continental Drive, Newark, DE 19713".
Read on the Try Ageless site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
"Every batch independently tested for potency and sterility" is asserted, and nothing is published to check it against: no certificate of analysis, no lot number, no testing laboratory and no potency or sterility result appears on the site. The assertion is more specific than most — it names potency and sterility rather than gesturing at "quality" — which makes the absence of a single document more conspicuous, not less. There is also nobody to ask for one, because the pharmacy holding those records is never identified.
Read on the Try Ageless site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
No state list is published. Try Ageless says its clinicians are U.S.-licensed and describes review as "same-day in most states", but publishes no included set and no excluded set anywhere on its weight-loss pages, so there was nothing for us to check ourselves and no coverage is claimed below.
Read the full licensing claim
"Licensed U.S. Clinicians · Independent providers", with clinician review described as "same-day in most states". No state list, included set or excluded set is published anywhere on the weight-loss pages, so no coverage claim is tested here and none is asserted.
Read on the Try Ageless site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with Try Ageless
We went through Try Ageless’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Open any product page and read the price. The semaglutide injection page prints it before you answer a single question.
- Start the free online evaluation, which promises it takes under two minutes.
- Say how you would describe your current approach to weight management: actively managing, some efforts, or no active efforts.
- Rate your physical activity level: sedentary, light, moderate or vigorous.
- Say what dietary plan you follow, if any.
- Search and add every medication, supplement, vitamin and topical cream you use, or tap "I don't take any medications".
- Answer whether you have any allergies.
- Answer whether you have any medical condition, prior surgery, or anything else for the doctor.
- Read a screen saying you are thirty seconds away from your plan, and continue.
- Hand over an email address, then a first name, a last name and a password to create an account before going further.
- The price comes first, which is rarer than it should be. The semaglutide injection page shows $99 beside a struck-through $229 for a month supply, with no question asked and no email taken.
- That lower figure is an introductory rate, not the standing one. The same page adds that exact pricing depends on your prescribed dose and that the final amount is shown after clinical review.
- Six health questions is the whole intake, and none of them asks your height, weight, date of birth or state. Those sit behind the account wall.
- The intake ends at a password. After the six questions it asks for an email, then a first name, last name and password, plus agreement to the terms, privacy policy and telehealth consent. We stopped at that gate, so no dose-specific price was ever displayed to us.
- Every page carries the line "Transparent pricing with no hidden fees" while the product page defers the real number to a clinician's review, so the two sentences pull against each other.
- A coupon code, GLP150, is printed on the product page beside the price, which tells you the headline figure is a promotion rather than a rate card.
Try Ageless support
- Phone
- (310) 361-7849
- hello@tryageless.com
Assessment
What holds up, and what does not
- Both injectable claims name their trial, their duration and the right molecule — "14.9% … over 68 weeks" for semaglutide and the 72-week SURMOUNT-1 figure for tirzepatide — and both check out in the registry.
- It states its compounding category outright, "state-licensed 503A pharmacies", where most of the companies we track state none.
- The ongoing month-to-month price is published beside the prepay ladder, with both the total and the per-month equivalent shown, so the arithmetic behind "From $199/mo" is visible rather than implied.
Show 2 more
- The claim FDA cited against its operator's other website — "same active ingredient as Wegovy" — appears zero times here; its nearest wording is the more careful "the compounds behind the leading branded GLP-1 treatments".
- Side effects are given with frequencies and a time course (">10% of patients", "most common in the first 2–4 weeks") rather than a single reassuring sentence.
- It sells sublingual tirzepatide drops, and no completed registered trial has tested tirzepatide by any non-injected route — 91 completed studies, every one an injection.
- Its operator is the company FDA wrote to about compounded GLP-1 claims: the footer names Lovely Meds, Inc., which received warning letter 716829 on September 9, 2025 over claims on lovelymeds.com. No letter names Try Ageless.
- "Every batch independently tested for potency and sterility" is asserted with no certificate of analysis, lot number or laboratory published, and no pharmacy named to request one from.
Show 3 more
- The homepage still shows tiles at $119 and $169 whose product pages are gone — a storefront advertising prices you cannot actually buy.
- "Greater average weight loss than semaglutide" is supported on the page only by two separate trials, and a cross-trial difference is not a head-to-head.
- No state list is published, so "same-day in most states" cannot be checked against anything.
Verdict
The bottom line
The two injections are cited properly, which is what makes the third product hard to defend. Three separate ClinicalTrials.gov queries return zero completed studies of sublingual tirzepatide, against 91 for the molecule generally — every one of them an injection. Buying the sublingual means buying a route nobody has tested.
Opens tryageless.com. A link is not a recommendation to take anything.
The two claims that hold up
Most reviews on this site begin by taking a claim apart. These two survive.
"Average 14.9% body weight loss in Phase 3 trials over 68 weeks."
That is STEP-1 — NCT03548935, phase 3, Completed, 1,961 participants — and the number, the duration and the molecule all match the registry entry. Try Ageless attributes it to "Phase 3 trials" rather than to its own product, and states the trial length rather than leaving 14.9% hanging as an open promise. Both of those are choices, and most of this category makes the other one.
The tirzepatide claim is the same shape: the 72-week SURMOUNT-1 figure, correctly named, correctly dated, attached to the right molecule.
Two caveats belong on both. STEP-1 and SURMOUNT-1 gave lifestyle intervention to every arm, so neither figure is what the drug does by itself. And both trials tested the approved, branded injectable — not the compounded preparation Try Ageless actually dispenses, which has never been through a registered trial.
Full analysis — 3 more sectionsThe product with no trial behind it · Who operates Try Ageless · Two prices for the same drug, on the same day
The product with no trial behind it
"Tirzepatide Drops — Daily sublingual liquid drops — tirzepatide without the needle. […] The lowest-cost tirzepatide format."
Checked on 11 August 2026 against the ClinicalTrials.gov v2 API:
- "sublingual tirzepatide" — 0 completed studies
- "tirzepatide sublingual" — 0
- "oral tirzepatide drops" — 0
- "tirzepatide", as a control — 91
The control is the part that makes the zeros mean something: the same query shape, against the same API, in the same pass, returns 91 completed studies for tirzepatide generally. Every one of them administered a once-weekly subcutaneous injection.
Route is not a detail here. Tirzepatide is a 39-amino-acid peptide, and peptides of that size are the textbook case of poor oral and mucosal absorption — the reason injection is the default rather than a preference. The one GLP-1 that reached approval in a swallowed form, semaglutide tablets, needed a dedicated absorption enhancer and its own phase 3 program to demonstrate that a usable amount arrived at all. Nothing equivalent has been published for tirzepatide by any non-injected route.
"USP-grade pharmaceutical purity" does not close that gap. Purity is a statement about the raw material; bioavailability is a statement about what reaches the blood. A perfectly pure peptide that is not absorbed is a perfectly pure peptide that does nothing.
What makes this worse than an untested product sitting quietly in a catalog is the framing: the drops are $199 a month against $235 for the injection, and are marketed as "the lowest-cost tirzepatide format". The saving is the pitch — and a thinner one than it was, because on 11 August the same comparison read $199 against $349. A reader economizing is invited to swap a form with 91 completed trials behind it for one with none.
Who operates Try Ageless
The footer:
"© 2026 Try Ageless · Operated by Lovely Meds, Inc · 131 Continental Drive, Newark, DE 19713"
FDA issued a warning letter to Lovely Meds, Inc. dba Lovely Meds on 9 September 2025 ([MARCS-CMS 716829](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lovely-meds-inc-dba-lovely-meds-716829-09092025)). It reviewed lovelymeds.com, a different website, and cited two claims — "Same active ingredient as Wegovy and Ozempic" and "Same active ingredient as Zepbound & Mounjaro" — as false or misleading advertising for compounded drugs under FDCA 502(a) and 502(bb). It alleges nothing about sterility, potency or product quality.
No letter names Try Ageless or tryageless.com, which is why this review does not file one against it. But the operator named in the footer is the recipient, and that is worth a reader knowing.
One point in Try Ageless's favor, and it is checkable: the claim FDA objected to does not appear on this site. "Same active ingredient" returns zero occurrences across its weight-loss page and its homepage. The nearest wording is "the compounds behind the leading branded GLP-1 treatments" — a different sentence, and a more careful one.
Two prices for the same drug, on the same day
Try Ageless publishes its weight-loss prices twice, and the two do not agree. On 25 August 2026 the treatments page priced the semaglutide injection at $175 a month while that product's own page priced it at $99, struck from $229. The tirzepatide drops were $199 on the treatments page and $249 on the product page. Neither page acknowledges the other, and the product pages add a caveat the treatments page does not: exact pricing depends on the prescribed dose, and the final amount appears only after clinical review.
The tirzepatide injection resolves the disagreement by removing one side — its product URL now redirects to the treatments page, so the ladder is the only price for it the site publishes.
This section previously said the homepage rendered tiles at $119 and $169 whose product pages no longer existed, and that nothing could be bought at those prices. That was checked again on 25 August 2026 and it is not right: those pages return HTTP 200 and the figures belong to other products — the $169 is NAD+ 1200 mg, and $119 is now the struck-through original on MIC+B12, not a live price for a GLP-1.
Questions
Frequently asked questions
Is there evidence for sublingual tirzepatide?
No. Three separate searches of ClinicalTrials.gov on 11 August 2026 — "sublingual tirzepatide", "tirzepatide sublingual" and "oral tirzepatide drops" — each return zero completed studies, while a bare "tirzepatide" query in the same pass returns 91. All 91 used a once-weekly subcutaneous injection. Tirzepatide is a 39-amino-acid peptide, and absorption across the mouth's mucosa is precisely what has never been demonstrated for it; the only swallowed GLP-1 to reach approval needed a purpose-built absorption enhancer and its own phase 3 program. Purity claims do not answer this — a pure peptide that is not absorbed still does nothing.
Has Try Ageless had an FDA warning letter?
Try Ageless has not; its operator has. The footer reads "Operated by Lovely Meds, Inc", and FDA issued Lovely Meds, Inc. dba Lovely Meds a warning letter on 9 September 2025 (MARCS-CMS 716829) about claims on lovelymeds.com — a different website. The letter is an advertising and labeling finding and alleges nothing about product quality. It names neither Try Ageless nor tryageless.com, which is why no letter is filed against this company here. Worth adding: the claim FDA cited does not appear on Try Ageless's site at all.
What does Try Ageless actually cost?
Read on 25 August 2026, month to month: $175 for the semaglutide injection, $235 for the tirzepatide injection, $199 for the tirzepatide drops. The per-month figures the cards lead with are yearly prepayments divided by twelve — $1,188 for semaglutide, $1,800 for tirzepatide and $1,908 for the drops. Two cautions. Each product's own page quotes a different number than the treatments page does, and both say the final amount is set after clinical review, so none of these is the figure you are certain to be charged. And they move: every price this review recorded on 11 August had changed a fortnight later, except the drops.
Which pharmacy fills a Try Ageless prescription?
It does not say. The site states "compounded by state-licensed 503A pharmacies" and "no overseas product", with no pharmacy name, state, license number or address anywhere. Naming the 503A category at all is more than most of the companies we track do; naming the pharmacy would be more than nearly any of them do. The practical consequence is that its batch-testing claim — "every batch independently tested for potency and sterility" — has no document published behind it and nobody identified to request one from.
Glossary
Key terms
Show definitions
- Sublingual
- Administered under the tongue, so the drug is meant to cross the mucous membrane of the mouth directly into the bloodstream rather than being injected or swallowed. Whether a given molecule actually crosses is a question that has to be measured, not assumed, and it is measured per molecule.
- Bioavailability
- The proportion of an administered dose that reaches the bloodstream unchanged. Injection is near-total by definition; every other route has to prove itself. Large peptides typically have very low oral and mucosal bioavailability, which is why injection is the default for this drug class.
- 503A pharmacy
- A compounding pharmacy licensed and inspected by its state board, preparing medicines for individual patients against a prescription. Its products are not FDA-approved and have not been through the approval process the branded product went through.
Compare
Others selling what Try Ageless sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Try Ageless's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.